Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05182294
Other study ID # 1319877
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 25, 2022
Est. completion date January 31, 2023

Study information

Verified date April 2023
Source Temple University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In the care of patients experiencing an acute exacerbation of COPD, supplemental oxygen therapy is often required. Oxygen is typically administered at flow rates between 1 and 4 liters per minute. High-flow nasal therapy (HFNT) has been reported to have beneficial effects in patients with hypoxemic respiratory failure and in hospitalized and non-hospitalized patients with severe COPD. Clinical efficacy in improving gas exchange depends upon patient tolerance and device-related properties such as flow rate and creation of turbulent flow in the conducting airways to improve oxygenation and carbon dioxide elimination. Alterations of nasal prong structure, such as nasal prong dimensions, may produce more robust turbulent flow at lower flow rates thereby improving gas exchange as well as patient tolerance. In this pilot study we will assess the impact of a new nasal cannula with asymmetric cannula dimensions that may create more turbulent flow at lower flow rates compared to the current symmetric nasal cannula on patient comfort as well as vital signs, pulse oximetry, breathing pattern and parameters of gas exchange in hospitalized patients with a COPD exacerbation.


Description:

AIRVO 2: The AIRVO 2 is a humidifier with integrated flow generator that delivers warmed and humidified respiratory gases to spontaneously breathing patient through a variety of patient interfaces. This is an FDA-approved 510k device for use in hospitals and nursing homes. During HFNT, oxygen will be passed through a heated humidifier (AIRVO 2, Fisher and Paykel Healthcare) and applied continuously through conventional large-bore binasal symmetric prongs or the new asymmetric prongs cannula device, with a gas flow rate of 20-35 liters per minute or as high as the patient will tolerate and an FiO2 to keep SaO2 ≥ 90% (Airvo 2, Fisher and Paykel Healthcare). Gas flow temperature will be adjusted based on patient's comfort and range from 34-37 degrees centigrade. After completion of the study, patients will be switched back to oxygen therapy administered by nasal prongs or mask. This is a pilot study in which the primary outcome is to determine the level of comfort experienced by the patient of using high-flow nasal oxygen administered by two different nasal cannulas. It is not an efficacy trial and there is no formal power analysis. All subjects are randomly assigned to two sequences, and each subject is treated subsequently with two treatments, the order of the treatments depends on its sequence. Initially, the primary endpoint and secondary endpoints will be evaluated for a carryover effect, a period effect, and a treatment effect with the use of two-tailed t-tests. We will then model treatment effects, period effects, and carryover effects using the linear mixed-effects model for this 2x2 crossover study. Subjects may discontinue participation in the study at any point and for any reason. This decision will not be held against them in any way. If a subject decides to withdraw, the physician will assess their clinical condition and determine the best course of action for the subject. This may include alternative methods of oxygen administration. Any data that is collected up to the point of subject withdrawal will be retained for analysis. Risks to Subjects The AIRVO 2 is an FDA cleared device (510k number K131895). There are few expected side effects of using the AIRVO 2 device - if the humidification is too low, the subject may experience nasal/throat discomfort or epistaxis. It has been determined to be a non-significant risk device in that it meets none of the criteria for a significant risk device. Potential Benefits to Subjects Potential benefits of study participation include the subject experiencing a decreased work of breathing with high flow nasal therapy provided by one or both of the nasal cannulas. It is also possible that the subject will experience no direct benefit. Privacy and Confidentiality All data will be stored on the REDCap website. The site is 21 CFR part 11 compliant. All study personnel have been trained in human subjects protections and good clinical practices. Study data will only be accessible to study personnel via password protected websites and computer terminals. A "HIPAA Authorization English (HRP-505)" has been provided with this submission. Economic Burden to Subjects All subjects will need supplemental oxygen as part of their clinical care. The only difference for this research is that the subjects will receive high-flow oxygen through two different nasal cannulas. There is no additional charge for this method of oxygen delivery.


Recruitment information / eligibility

Status Completed
Enrollment 14
Est. completion date January 31, 2023
Est. primary completion date December 14, 2022
Accepts healthy volunteers No
Gender All
Age group 40 Years and older
Eligibility Inclusion Criteria: i.aged = 40 years (ii) hospitalization for acute exacerbation of COPD; (iii) smoker or ex-smoker (iv) FEV1 <80% of predicted and FEV1/FVC <70% postbronchodilator within 12 months prior to admission (v) have no other lung disease (including asthma) as a principal cause of pulmonary function limitation (vi) baseline PaCO2 = 45 mm Hg at study entry. (vii) willing to give informed consent (viii) willing to participate in measurement of ABGs (ix) will to provide a brief history and physical examination and answer questionnaires. Exclusion Criteria: - Adults unable to consent - Individuals who are not yet adults (infants, children, teenagers) - Women who are known to be pregnant at the time of hospital admission - Prisoners - Individuals who do not understand English

Study Design


Related Conditions & MeSH terms


Intervention

Device:
AIRVO 2, the new asymmetric nasal cannula
The AIRVO 2 is a humidifier with integrated flow generator that delivers warmed and humidified respiratory gases to spontaneously breathing patient through a variety of patient interfaces. This is an FDA-approved 510k device for use in hospitals and nursing homes. During HFNT, oxygen will be passed through a heated humidifier (AIRVO 2, Fisher and Paykel Healthcare) and applied continuously through conventional large-bore binasal symmetric prongs or the new asymmetric prongs cannula device, with a gas flow rate of 20-35 liters per minute or as high as the patient will tolerate and an FiO2 to keep SaO2 = 90% (Airvo 2, Fisher and Paykel Healthcare). Gas flow temperature will be adjusted based on patient's comfort and range from 34-37 degrees centigrade. After completion of the study, patients will be switched back to oxygen therapy administered by nasal prongs or mask..

Locations

Country Name City State
United States Temple University Hospital Philadelphia Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
Temple University Fisher and Paykel Healthcare

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Determining the level of comfort experienced by the patient of using high-flow nasal oxygen administered by two different nasal cannulas. This is a pilot study in which the primary outcome is to determine the level of comfort experienced by the patient of using high-flow nasal oxygen administered by two different nasal cannulas. The level of comfort will be assessed by a 100 mm visual analog scale from 0 (no discomfort) to 100 (maximal imaginable discomfort) 6 hours
Primary Sensation of shortness of breath Likert scale model indicating marked improvement (+2), slight improvement (+1), no change (0), slight deterioration (-1) and marked deterioration (-2) in patient's sensation of shortness of breath and overall comfort 6 hours
See also
  Status Clinical Trial Phase
Terminated NCT05418777 - Treatment of Pneumocystis in COPD (the TOPIC Study) Phase 1/Phase 2
Not yet recruiting NCT05649891 - Checklists Resuscitation Emergency Department N/A
Completed NCT03286855 - Effectiveness of Vibrating Mesh Versus Small Volume Nebuliser in Chronic Obstructive Pulmonary Disease (COPD) N/A
Recruiting NCT06021990 - Clopidogrel for the Prevention of Exacerbations in Severe COPD Phase 3
Completed NCT05218525 - Testing a Prediction Algorithm Into a Running Telehealth System for Patients With COPD N/A
Recruiting NCT06149494 - RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection Phase 2
Recruiting NCT05734365 - COPD-ICU Multicentre Prospective Observational Register
Completed NCT03464695 - Automated Oxygen Delivery by O2matic to Patients Admitted With an Exacerbation in COPD N/A
Recruiting NCT04881409 - Nasal High-flow Compared to Non-invasive Ventilation in Treatment of Acute Acidotic Hypercapnic Exacerbation of Chronic Obstructive Pulmonary Disease N/A
Completed NCT04821869 - ProAir Digihaler in COPD Disease Management: A Real World Study
Recruiting NCT06274957 - The Effect of Airway and Chest Wall Oscillation on Respiratory Functions in COPD Patients in Acute Exacerbation N/A
Recruiting NCT05783544 - Impact of A. Lumbricoides on Pulmonary Aspergillosis Development N/A
Recruiting NCT06331416 - Multiparametric Home Telemonitoring of Patients With Chronic Obstructive Pulmonary Disease Exacerbation N/A
Not yet recruiting NCT05703919 - Standard vs Targeted Oxygen Therapy Prehospital for Chronic Obstructive Pulmonary Disease Phase 4
Not yet recruiting NCT06419036 - The Use of Medical Devices to Monitor Chronic Obstructive Pulmonary Disease Patients Study BREATH-TRACHER 1
Not yet recruiting NCT06419062 - The Use of Medical Devices to Monitor Chronic Obstructive Pulmonary Disease Patients Study BREATH-TRACHER 2
Recruiting NCT05764993 - Prevalence of Humoral Dysfunction in Pts With Frequent Exacerbations of COPD, and the Effect of SCIgR for Prevention Phase 2
Completed NCT06040931 - Airway Inflammation, Small Airways Dysfunction, and Frequency of Exacerbations in COPD N/A
Active, not recruiting NCT04192175 - Identification of Patients Admitted With COPD Exacerbations and Predicting Readmission Risk Using Machine Learning
Recruiting NCT03680495 - Steroid Resistance During COPD Exacerbations With Respiratory Failure